BACKGROUND: Asparaginase poses a substantial risk for hypersensitivity reactions during and after administration; however, these reactions vary by asparaginase formulation and administration route. It is imperative that nurses be knowledgeable of clinical symptoms associated with intravenous (IV) monomethoxypolyethylene glycol (PEG)-asparaginase reactions, as well as potential reaction timing. PURPOSE: This single institution retrospective study describes the clinical factors among patients with IV PEG-asparaginase hypersensitivity reactions. METHODS: Reaction frequency and severity, dose, phase of treatment, and time between infusion initiation and reaction were collected on patients identified as having an IV PEG-asparaginase hypersensitivity reaction while undergoing acute lymphoblastic leukemia treatment. RESULTS: Sixty-three patients (12.8%) developed a hypersensitivity reaction to IV PEG-asparaginase, with the reaction occurring during a median of 3 doses in both risk arms. Reactions were noted ≤60 minutes after infusion initiation in 98% of patients, and no reactions were fatal. CONCLUSION: Nurses should carefully observe patients throughout the infusion and anticipate adverse reactions, particularly during the first 3 doses and first 10 minutes of each infusion. Patient and family education should include the rare risk of delayed reactions.
BACKGROUND:Asparaginase poses a substantial risk for hypersensitivity reactions during and after administration; however, these reactions vary by asparaginase formulation and administration route. It is imperative that nurses be knowledgeable of clinical symptoms associated with intravenous (IV) monomethoxypolyethylene glycol (PEG)-asparaginase reactions, as well as potential reaction timing. PURPOSE: This single institution retrospective study describes the clinical factors among patients with IV PEG-asparaginasehypersensitivity reactions. METHODS: Reaction frequency and severity, dose, phase of treatment, and time between infusion initiation and reaction were collected on patients identified as having an IV PEG-asparaginasehypersensitivity reaction while undergoing acute lymphoblastic leukemia treatment. RESULTS: Sixty-three patients (12.8%) developed a hypersensitivity reaction to IV PEG-asparaginase, with the reaction occurring during a median of 3 doses in both risk arms. Reactions were noted ≤60 minutes after infusion initiation in 98% of patients, and no reactions were fatal. CONCLUSION: Nurses should carefully observe patients throughout the infusion and anticipate adverse reactions, particularly during the first 3 doses and first 10 minutes of each infusion. Patient and family education should include the rare risk of delayed reactions.
Authors: Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis Journal: Blood Date: 2014-01-21 Impact factor: 22.113
Authors: Louise Tram Henriksen; Arja Harila-Saari; Ellen Ruud; Jonas Abrahamsson; Kaie Pruunsild; Goda Vaitkeviciene; Ólafur Gísli Jónsson; Kjeld Schmiegelow; Mats Heyman; Henrik Schrøder; Birgitte Klug Albertsen Journal: Pediatr Blood Cancer Date: 2014-11-21 Impact factor: 3.167
Authors: Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling Journal: J Pharmacol Exp Ther Date: 2015-01-08 Impact factor: 4.030
Authors: Lynda M Vrooman; Jeffrey G Supko; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis Clavell; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman Journal: Pediatr Blood Cancer Date: 2010-02 Impact factor: 3.167
Authors: Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: J Clin Oncol Date: 2019-06-12 Impact factor: 44.544
Authors: Hope D Swanson; John C Panetta; Patricia J Barker; Yiwei Liu; Hiroto Inaba; Mary V Relling; Ching-Hon Pui; Seth E Karol Journal: Blood Date: 2020-01-02 Impact factor: 22.113
Authors: Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia Journal: Adv Drug Deliv Rev Date: 2021-12-10 Impact factor: 15.470